ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1343

Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database

Philip Mease1, Pamela Young2, David Gruben3, Lara Fallon4, Rebecca Germino5 and Arthur Kavanaugh6, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Pfizer Inc, Collegeville, PA, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, Montreal, QC, Canada, 5Pfizer Inc, New York, NY, 6UC San Diego Health System, San Diego, CA

Meeting: ACR Convergence 2020

Keywords: Cohort Study, Disease-Modifying Antirheumatic Drugs (Dmards), Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). It was approved in the US in December 2017 for use in combination with non-biologic DMARDs. This analysis of real-world data assessed demographic and baseline clinical characteristics, as well as treatment persistence/adherence, in patients (pts) with PsA who had newly initiated tofacitinib treatment.

Methods: This retrospective cohort study included pts aged ≥ 18 years in the Truven MarketScan™ US Commercial and Medicare Supplemental Claims and Encounters database with ≥ 1 tofacitinib claim (first = index) between December 14, 2017–April 30, 2019, and PsA diagnoses (≥ 1 inpatient or ≥ 2 outpatient [30–365 days apart]) on or within 12 months pre-index. Pts were continuously enrolled for 12 months pre-index and 6 months post-index, with no pre-index claims for tofacitinib. Pt demographic and clinical characteristics on the day of index, history of treatment with advanced therapies (≥ 1 claim for biologic DMARDs or apremilast within 12 months pre-index), and tofacitinib treatment regimen (monotherapy or combination therapy [≥ 1 claim for conventional synthetic DMARDs or apremilast on or within 90 days post-index]) were recorded. Outcomes at 6 months post-index included tofacitinib persistence (< 60-day gap without tofacitinib treatment) and adherence (proportion of days covered ≥ 80% and medication possession ratio [data not shown]). A sensitivity check was performed by analyzing a sub-cohort which excluded pts with a diagnosis of rheumatoid arthritis (RA) on or within 12 months pre-index and within 6 months post-index.

Results: Of 17,321 pts receiving tofacitinib, 440 pts met the inclusion criteria for the overall cohort, with 315 pts included in the sub-cohort. In the overall cohort, pts were mostly female, with a mean age of 52.3 years and a mean PsA duration of 738 days (Table 1). Most pts were exposed to ≥ 1 advanced therapy (mean = 1.1; range = 0–4) within 12 months pre-index; most commonly secukinumab (Table 2). Overall, 39.3% of patients received tofacitinib combination therapy post-index; most commonly methotrexate (Table 2). Persistence was similar in pts receiving tofacitinib monotherapy (71.2%) vs combination therapy (73.4%; Table 3) at 6 months post-index. Adherence was slightly lower in pts receiving tofacitinib monotherapy (56.9%) vs combination therapy (66.5%; Table 3) at 6 months post-index. All results were similar in the sub-cohort (Tables 1–3).

Conclusion: This analysis of US-based claims data indicated that pts newly initiated tofacitinib treatment an average of 2 years after PsA diagnosis, with the majority ( > 60%) of pts receiving tofacitinib as monotherapy. High levels of persistence and adherence to tofacitinib were observed 6 months after treatment initiation. Findings were similar when pts with PsA who also had a diagnosis of RA were excluded. Data are limited in that claims data cannot confirm that pts took the medication for which they filed a claim for.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by Gemma Turner, CMC Connect, and funded by Pfizer Inc.


Disclosure: P. Mease, Amgen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, 8, Sun, 2, 5, UCB, 2, 5, 8, AbbVie, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, GlaxoSmithKline, 5; P. Young, Pfizer Inc, 1, 3; D. Gruben, Pfizer Inc, 1, 3; L. Fallon, Pfizer Inc, 1, 3; R. Germino, Pfizer Inc, 1, 3; A. Kavanaugh, Eli Lilly and Company, 5.

To cite this abstract in AMA style:

Mease P, Young P, Gruben D, Fallon L, Germino R, Kavanaugh A. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/early-real-world-experience-of-tofacitinib-for-psoriatic-arthritis-data-from-a-united-states-healthcare-claims-database/. Accessed February 4, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-real-world-experience-of-tofacitinib-for-psoriatic-arthritis-data-from-a-united-states-healthcare-claims-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences